Hyperhomocysteinemia due to pernicious anemia leading to pulmonary thromboembolism in a heterozygous mutation carrier

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 3, 2008, Pages 365-368

  Küpeli, Elif ^a   Cengiz, Cem ^a   Cila, Ayşenur ^a   Karnak, Demet ^b  

^a Mesa Hospital Cankaya   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Hyperhomocysteinemia; Pernicious anemia; Pulmonary thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; D DIMER; ENOXAPARIN; FERRITIN; FERROGLYCINE SULFATE; FOLIC ACID; GLYCINE DERIVATIVE; HOMOCYSTEINE; PARIETAL CELL ANTIBODY; PROTHROMBIN; PYRIDOXINE; THIAMINE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ERYTHROCYTE VOLUME; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMOPTYSIS; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; IRON DEFICIENCY ANEMIA; LUNG ANGIOGRAPHY; LUNG ARTERY; LUNG EMBOLISM; PERNICIOUS ANEMIA; PRIORITY JOURNAL; SUPPLEMENTATION; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ANEMIA, PERNICIOUS; FEMALE; HETEROZYGOTE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; PROTHROMBIN; PULMONARY EMBOLISM;

EID: 45749106731     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607305101     Document Type: Article

References (14)

1. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003 ; 58: 470-484.
2. Hainaut P., Jaumotte C., Verhelst D., et al. Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in elderly and in idiopathic cases. Thromb Res. 2002 ; 106: 121-125.
3. den Heijer M., Koster T., Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 ; 334: 759-762.
4. Ray JG Meta-analyses of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998 ; 158: 2101-2106.
5. den Heijer M., Rosendaal FR, Blom HJ, Gerrits WB, Bos GM Hyperhomocysteinemia and venous thrombosis: a meta-analyses. Thromb Haemost. 1998 ; 80: 874-877.
6. McCully KS Homocysteine and vascular disease. Nat Med. 1996 ; 2: 386-389.
7. Eichinger S., Stümpflen A., Hirshl M., et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998 ; 80: 566-569.
8. Langman LJ, Ray JG, Evrovski J., Yeo E., Cole DE Hyperhomocysteinemia and the increased risk of venous thromboembolism. Arch Intern Med. 2000 ; 160: 961-964.
9. Dani SI, Thanvi S., Shah JM, Prajapti J., Jain S., Joshi H. Hyperhomocysteinemia masquerading as pulmonary embolism. JAPI. 2003 ; 51: 914-915.
10. Caldera A., Mora J., Kottler M., Eiger G. Pulmonary embolism in a patient with pernicious anemia and hyperhomocysteinemia. Chest. 2002 ; 122: 1487-1488.
11. Eichinger S., Minar E., Hirschl M., et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999 ; 81: 14-17.
12. Baglin T., Luddington R., Brown K., Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003 ; 362: 523-526.
13. Tsai AW, Cushman M., Tsai MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: longitudinal investigation of thromboembolism etiology (LITE). Am J Hematol. 2003 ; 72: 192-200.
14. Brown K., Luddington R., Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998 ; 79: 254-258.